

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	4821-411	To Be Assigned
	APPLICANT	
	J. YOUNG et al.	
	FILING DATE	GROUP
	January 29, 2001	To Be Assigned

U.S. PATENT DOCUMENTS

XAMINER IN TIAL	*E	DOCUMENT NUMBER	DAT E	NAME	CLA	SUBCLA	FILING DATE IF APPROPRIATE
					SS	SS	
	AA	6,127,363 \Rightarrow	10/2000	Doherty et al.	514	220	
	AB	5,795,880 \rightarrow	08/1998	Svec et al.	514	169	
	AC	5,780,051 \rightarrow	07/1998	Eswara et al.	424	449	
	AD	5,733,566 \rightarrow	03/1998	Lewis	424	426	
	AE	5,719,283 \rightarrow	02/1998	Bell et al.	544	262	
	AF	5,674,553 \rightarrow	10/1997	Shinoda et al.	427	68	
	AG	5,639,476 \Rightarrow	06/1997	Oshlack et al.	424	468	
	AH	5,591,767 \rightarrow	01/1997	Mohr et al.	514	413	
	AI	5,552,429 \rightarrow	09/1996	Wong et al.	514	415	
	AJ	5,459,164 \rightarrow	10/1995	Vargas	514	646	
	AK	5,436,272 \rightarrow	07/1995	Scheinbaum	514	646	
	AL	5,354,556 \rightarrow	10/1994	Sparks et al.	424	419	
	AM	5,250,534 \rightarrow	10/1993	Bell et al.	514	258	
	AN	5,120,548 \rightarrow	06/1992	McClelland et al.	424	473	
	AO	5,104,899 \Rightarrow	04/1992	Young et al.	514	646	
	AP	5,073,543 \rightarrow	12/1991	Marshall et al.	514	21	
	AQ	5,068,440 \rightarrow	11/1991	Jeffery et al.	564	442	
	AR	5,059,595 \rightarrow	10/1991	Le Grazie	424	468	
	AS	4,988,814 \rightarrow	01/1991	Abou-Ghribia et al.	544	295	
	AT	4,939,175 \rightarrow	07/1990	Ukai et al.	514	646	
	AU	4,929,629 \Rightarrow	05/1990	Jeffery	514	646	
	AV	4,871,774 \leftarrow	10/1989	Rees	514	646	
	AW	4,816,488 \leftarrow	03/1989	Rees	514	646	
	AX	4,814,352 \rightarrow	03/1989	Jeffery et al.	514	646	
	AY	4,806,570 \leftarrow	02/1989	Jeffery et al.	514	646	
	AZ	4,746,680 \rightarrow	05/1988	Jeffery et al.	514	646	
	BA	4,552,828 \rightarrow	11/1985	Toya et al.	430	217	
	BB	4,522,828 \rightarrow	06/1985	Jeffery et al.	514	646	
	BC	4,008,719 \rightarrow	02/1977	Theeuwes et al.	128	260	
	BD	3,960,891 \rightarrow	06/1976	Malen et al.	260	327	
	BE	3,916,899 \rightarrow	11/1975	Theeuwes et al.	128	260	
	BF	3,845,770 \leftarrow	11/1974	Theeuwes et al.	128	260	
	BG	3,598,123 \rightarrow	08/1971	Zaffaroni	128	268	

	BH	3,536,809	→	10/1970	Applezweig	424	28	
	BI	3,471,515	→	10/1969	Troxler et al.	260	326.15	
	BJ	3,155,670	→	11/1964	Janssen et al.	260	294	
	BK	3,155,669	←	11/1964	Janssen et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DAT E	COUNTRY	CLAS	SUBC LASS	TRANSLATION	
							YES	NO
	BL	WO 99/33450	→ 07/1999	PCT (in English)				
	BM	WO 98/13034	→ 04/1998	PCT (in English)				
	BN	WO 98/13033	→ 04/1998	PCT (in English)				
	BO	WO 98/11884	← 03/1998	PCT (in English)				
	BP	WO 98/06722	02/1998	PCT				X _(abs)
	BQ	EP 0 781 561 A1	→ 07/1997	EPO (in English)				
	BR	WO 97/20810	→ 06/1997	PCT (in English)				
	BS	WO 97/03675	→ 02/1997	PCT (in English)				
	BT	WO 95/21615	→ 08/1995	PCT (in English)				
	BU	WO 95/20949	→ 08/1995	PCT (in English)				
	BV	WO 94/28902	→ 12/1994	PCT (in English)				
	BW	WO 94/00114	→ 01/1994	PCT (in English)				
	BX	WO 94/00047	→ 01/1994	PCT (in English)				
	BY	WO 90/06110	→ 06/1990	PCT (in English)				
	BZ	WO 88/06444	→ 09/1988	PCT (in English)				
	CA	DE 32 12 682 A1	→ 10/1982	Germany				X _(abs)
	CB	GB 2098602 A	→ 11/1982	United Kingdom				
	CC	EP 0 035 597	→ 9/1981	Europe				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

→	CD	Baldessarini et al., <i>Life Sciences</i> 39: 1765-1777, (1986).
→	CE	Buckett et al., "BTS 54 524-An Approach to Rapidly Acting Antidepressant," <i>New Concepts in Depression</i> 2: 167-172 (1988).
→	CF	Bucket et al., "The Pharmacology of Sibutramine Hydrochloride (BTS 54 524), A New Antidepressant which induces Rapid Noradrenergic Down-Regulation", <i>Prog. Neuro-Psychopharmacol. & Biol. Psychiat.</i> 12: 575-584 (1988).
	CG	Buckett et al., "Sibutramine Hydrochloride," <i>Drugs of the Future</i> 13(8): 736-738 (1988).
→	CH	Butler, D., <i>Facile Cycloalkylation of Arylacetanitriles in Dimethyl Sulfoxide</i> , <i>J. Org. Chem.</i> , 36:1308-1309 (1971)
→	CI	Canonne, P., et al., <i>Effet du Benzene Dans la Reaction de Grignard sur les Nitriles</i> , <i>Tetrahedron Lett.</i> , 21:155-58 (1980)
→	CJ	Carstensen, J., <i>Drug Stability: Principles & Practice</i> , 2d. Ed., pp. 379-80, Marcel Dekker, NY, NY, (1995).
→	CK	Castello, R.A., et al., <i>Discoloration of Tablets Containing Amines and Lactose</i> , <i>Pharm. Sci.</i> 51(2):106-108 (1962)
→	CL	Cheetham, S.C., et al., <i>³H]Paroxetine Binding in Rat Frontal Cortex Strongly Correlates with ³H]5-HT Uptake: Effect of Administration of Various Antidepressant Treatments</i> , <i>Neuropharmacology</i> (1993), 32(8), 737-743
→	CM	Cliffe et al., (S)-N-tert-Butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide [(S)-WAY-100135]: A Selective Antagonist at Presynaptic and Postsynaptic 5-HT _{1A} Receptors, <i>Med. Chem.</i> , 36:1509-1510 (1993)
→	CN	<i>Diagnostic and Statistical Manual of Mental Disorders</i> , Fourth Ed., American Psychiatric Association, (1997).
→	CO	<i>Diagnostic and Statistical Manual of Mental Disorders</i> , 3rd Ed., American Psychiatric Association (1981).
→	CP	Dreshfield et al., <i>Enhancement of Fluoxetine-Dependent Increase of Extracellular Serotonin (5-HT) Levels by (-)-Pindolol, an Antagonist at 5-HT_{1A} Receptors</i> , <i>Neurochem. Res.</i> , 21(5):557-562 (1996)
→	CQ	Eliel, E.L., <i>Stereochemistry of Carbon Compounds</i> (McGraw-Hill, NY, 1962).

Sheet 3 of 5

—	CR	Evans et al., "Prevalence of Alzheimer's Disease in a Community Population of Older Persons," <i>J.A.M.A.</i> 262 : 2551-2556 (1989).
→	CS	Fuentes, J. et al., "Comparison of the apparent anti-depressant activity of (-) and (+) tranylpromine in an animal model", <i>Chemical Abstracts</i> , 85 : 7, page 31, No. 40768t (1976).
→	CT	Goodman & Gilman, <i>The Pharmacological Basis of Therapeutics</i> , 362-373, 404 (9 th ed. McGraw-Hill, 1996)
→	CU	Gray et al., <i>The Involvement of the Opioidergic System in the Antinociceptive Mechanism of Action of Antidepressant Compounds</i> , <i>BR.J. Pharmacol.</i> , Vol. 124, No. 4, (1998) pp 669-674
→	CV	Handbook of Pharmaceutical Excipients, 2 nd ed., Wade and Willer eds., pp. 257-259 (1994)
→	CW	Heal et al., <i>A Comparison of the Effects on Central 5-HT Function of Sibutramine Hydrochloride and Other Weight-Modifying Agents</i> , <i>BR.J. Pharmacol.</i> (1998), 125 (2), 301-308
→	CX	Hillyer et al., (S)-5-Fluoro-8-hydroxy-2-(dipropylamino)tetralix: A Putative 5-HT _{1A} Receptor Antagonist, <i>J. Med. Chem.</i> , 33 :1541-44 (1990)
↑	CY	<i>J. Med. Chem.</i> , Vol. 36, No. 17, 2540 (1993)
→	CZ	<i>Introduction to Pharmaceutical Dosage Forms</i> , 4th ed., Lea & Febiger, Philadelphia (1985).
→	DA	Jacques et al., "Enantiomers, Racemates and Resolutions," (Wiley-Interscience, NY, 1981).
→	DB	Jamali et al., <i>Journal of Pharmaceutical Sciences</i> , 78 : 9: 695-715 (1989)
→	DC	Jeffery et al., <i>Synthesis of Sibutramine, A Novel Cyclobutylalkylamine Useful in the Treatment of Obesity, and its Major Human Metabolites</i> , <i>J. Chem. Soc. Perkin. Trans. 1</i> , 2583-2589 (1996)
→	DD	King et al., "Clinical Pharmacology of Sibutramine Hydrochloride (BTS 54524) A New Antidepressant, in Healthy Volunteers," <i>Clinical Pharmac.</i> 26 : 607-611 (1989).
→	DE	Kula et al., "Effects of N-Substituted Phenyltetrahydropyridines on Cerebral High-Affinity Synaptosomal Uptake of Dopamine and Other Monoamines in Several Mammalian Species," <i>Life Sciences</i> 34 (26): 2567-2575, (1984).
→	DF	Luscombe et al., <i>The Contribution of Metabolites to the Rapid and Potent Down-Regulation of Rat Cortical β-Adrenoceptors by the Putative Antidepressant Sibutramine Hydrochloride</i> , <i>Neuropharmacology</i> , Vol. 28, No. 2, (1989) pp 129-134
→	DG	The Merck Manual of Diagnosis and Therapy, 17th Ed., Merck & Co., Inc., Whitehouse Station, NJ, (1999).
↑	DH	Middlemiss et al., <i>Centrally Active 5-HT Receptor Agonists and Antagonists</i> , <i>Neurosci. and Biobehv. Rev.</i> , 16 :75-82 (1992)
↑	DI	Moreau et al., <i>Behavioral Profile of the 5-HT_{1A} Receptor Antagonist (S)-UH-301 in Rodents and Monkeys</i> , <i>Brain Res. Bull.</i> , 29 :901-04 (1992)
→	DJ	Nakada et al., <i>An Enantioconvergent Route to (-)-Kainic Acid</i> , <i>Tetrahedron Lett.</i> , 38 :857-860 (1997)
	DK	<i>Physician's Desk Reference</i> ® 473-475 (53 rd ed., 1999)
	DL	<i>Physician's Desk Reference</i> ® 475-476 (53 rd ed., 1999)
	DM	<i>Physician's Desk Reference</i> ® 764-766 (53 rd ed., 1999)
	DN	<i>Physician's Desk Reference</i> ® 823-825 (53 rd ed., 1999)
	DO	<i>Physician's Desk Reference</i> ® 978-979 (53 rd ed., 1999)
	DP	<i>Physician's Desk Reference</i> ® 1054-1056 (53 rd ed., 1999)
	DQ	<i>Physician's Desk Reference</i> ® 1332-1334 (53 rd ed., 1999)
	DR	<i>Physician's Desk Reference</i> ® 1369-1370 (53 rd ed., 1999)
	DS	<i>Physician's Desk Reference</i> ® 1432-1436 (53 rd ed., 1999)
	DT	<i>Physician's Desk Reference</i> ® 1494-1498 (53 rd ed., 1999)
	DU	<i>Physician's Desk Reference</i> ® 1641-1645 (53 rd ed., 1999)
	DV	<i>Physician's Desk Reference</i> ® 2004-2009 (53 rd ed., 1999)
	DW	<i>Physician's Desk Reference</i> ® 2075-2078 (53 rd ed., 1999)
	DX	<i>Physician's Desk Reference</i> ® 2190-2192 (53 rd ed., 1999)
	DY	<i>Physician's Desk Reference</i> ® 2367-2368 (53 rd ed., 1999)
	DZ	<i>Physician's Desk Reference</i> ® 2396-2399 (53 rd ed., 1999)
	EA	<i>Physician's Desk Reference</i> ® 2490-2493 (53 rd ed., 1999)
	EB	<i>Physician's Desk Reference</i> ® 2516-2521 (53 rd ed., 1999)
	EC	<i>Physician's Desk Reference</i> ® 2688-2691 (53 rd ed., 1999)
	ED	<i>Physician's Desk Reference</i> ® 2701-2704 (53 rd ed., 1999)
	EE	<i>Physician's Desk Reference</i> ® 2720-2726 (53 rd ed., 1999)
	EF	<i>Physician's Desk Reference</i> ® 2735-2736 (53 rd ed., 1999)

Sheet 4 of 5

	EG	<i>Physician's Desk Reference® 2886-2888 (53rd ed., 1999)</i>
	EH	<i>Physician's Desk Reference® 2908-2910 (53rd ed., 1999)</i>
	EI	<i>Physician's Desk Reference® 3092-3094 (53rd ed., 1999)</i>
	EJ	<i>Physician's Desk Reference® 3101-3104 (53rd ed., 1999)</i>
	EK	<i>Physician's Desk Reference® 3224-3225 (53rd ed., 1999)</i>
	EL	<i>Physician's Desk Reference® 3267-3272 (53rd ed., 1999)</i>
	EM	<i>Physician's Desk Reference® 3307-3309 (53rd ed., 1999)</i>
	EN	<i>Physician's Desk Reference® 3383-3384 (53rd ed., 1999)</i>
	EO	<i>Physician's Desk Reference® 2520 (52nd ed., 1998)</i>
	EP	<i>Physician's Desk Reference® 2958 (52nd ed., 1998)</i>
—	EQ	<i>Remingtons: The Practice of The Science and Pharmacy</i> , 19 th ed., Gennaro, ed., p. 1625 (1995)
—	ER	<i>Remington's Pharmaceutical Sciences</i> , 18th ed., Mack Publishing, Easton PA (1990).
—	ES	<i>Remington's Pharmaceutical Sciences</i> , 16th ed., Mack Publishing, Easton PA (1980).
—	ET	Stock, M.J., <i>Sibutramine: A Review of the Pharmacology of a Novel Anti-Obesity Agent</i> , Int'l J. Obesity, 21(Supp. 1):S25-S29 (1997)
—	EU	<i>U.S. Pharmacopedia (USP) SP (XXI)/NF (XVI)</i>
—	EV	Wilen et al., <i>Tetrahedron</i> , 27:25-36 33(21) (1977).
—	EW	Wilen, S.H., <i>Tables of Resolving Agents and Optical Resolutions</i> 268 (E.L. Eliel ed., Univ. of Notre Dame Press, Notre Dame, IN, 1972).
EXAMINER		DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		